July 19, 2021 07:30 AM EDTUpdated 09:52 AM

Cytokinetics is getting its shot at a major PhIII showdown with Bristol Myers after posting positive data for a rare cardio disease. Shares rocket up

After losing a whole lot of market confidence in their lead drug, little Cytokinetics is now lining up for a crucial Phase III pivotal challenge …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cy­to­ki­net­ics is get­ting its shot at a ma­jor PhI­II show­down with Bris­tol My­ers af­ter post­ing pos­i­tive da­ta for a rare car­dio dis­ease. Shares rock­et up